Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Robert M. Campbell(Children's Health Queensland Hospital and Health Service), Xiang S. Ye(Eli Lilly (Spain)), Susan E. Pratt(Eli Lilly (Spain)), Courtney M. Tate(Eli Lilly (United States)), Denis McCann(Eli Lilly (United States)), Enrique Jambrina(Eli Lilly (Spain)), Alfonso de Dios(Eli Lilly (United States)), Nathan A. Brooks(Eli Lilly (United States)), Juan A. Velasco(Eli Lilly (Spain)), Edward M. Chan(Eli Lilly (Spain)), Mary M. Mader(Eli Lilly (United States)), Yong Wang(Qingdao University of Technology), James J. Starling(Eli Lilly (Spain)), Songqing Na(Eli Lilly (United States)), Raymond Gilmour(Eli Lilly (Spain)), Stephen H. Parsons(Eli Lilly (Spain)), Harold B. Brooks(Eli Lilly (United States)), Jeremy R. Graff(United Therapeutics (United States)), Bryan D. Anderson(Eli Lilly (Spain)), Chuan Shih(Eli Lilly (Spain)), Louis F. Stancato(Indiana Biosciences Research Institute)
Cited by 121
Related Papers
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Histone Modifications and Cancer
|Cold Spring Harbor Perspectives in Biology|2016|1.1k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
|Investigational New Drugs|2014|564
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
|Journal of Clinical Investigation|2007|377